/ /

  • linkedin
  • Increase Font
  • Sharebar

    Refractive year characterized by expanding array of treatment choices


    Stagnant LASIK market?

    Considering the aforementioned abundance of corrective technologies, the question arises regarding the status of LASIK and whether this market seems to be stagnant in the United States.

    “The number of patients undergoing LASIK will increase eventually because the number of refractive patients is increasing overall,” Dr. Gulani said. “At the same time the number of refractive choices also has increased, and hence, the number of patients choosing LASIK may appear to have remained stagnant.

    “Patients are now candidates for phakic implants, presbyopic corneal inlays, CXL, and refractive lens exchange rather than LASIK across the board,” he added. “So the patients that choose only LASIK are now distributed among the additional choices. This seems to be a more realistic way of evaluating the marketplace.”

    It will be interesting to see the effect of topography-guided LASIK, which was approved by the FDA, on the activity in this market.

    “This brings something new to the field,” said Dr. Hersh, noting the “superb” results that patients are attaining.

    Another potential game changer is approval of the SMILE procedure.

    “We are not seeing a lot of interest in this procedure yet in the United States, but with time, I believe we will see it evolving and being embraced more by surgeons,” Dr. Hersh predicted.


    Arun C. Gulani, MD, MS
    e: [email protected]
    Dr. Gulani has no financial interest in any aspect of this report.

    Peter Hersh, MD
    e: [email protected]
    Dr. Hersh holds stock in Avedro.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results